FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addres  Landry Rober	is of Reporting Persor $rac{E}{E}$	1*	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]		tionship of Reporting Per- all applicable) Director Officer (give title below)	son(s) to Issuer  10% Owner Other (specify below)
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/16/2020		EVP Finance	CFO
(Street) TARRYTOWN (City)	NY (State)	10591 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Rep Form filed by More that Person	orting Person

(City) (State)	(Zip)							Person		
	Table I - Non-Derivati	ive Securities A	cquire	d, D	isposed o	f, or B	eneficially (	Owned		
. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Yea	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquired (D) (Instr	(A) or . 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirec Beneficia Ownershi (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111311.4)
Common Stock	04/16/2020	)	M <sup>(1)</sup>		4,000	Α	\$272.7	28,373	D	
Common Stock	04/16/2020	)	F <sup>(1)</sup>		3,009	D	\$529.79	25,364	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		33	D	\$540.7	25,331	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		33	D	\$542.25	25,298	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		61	D	\$548.99	25,237	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		3	D	\$550	25,234	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		55	D	\$551.38	25,179	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		62	D	\$553.85	25,117	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		33	D	\$556.43	25,084	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		89	D	\$558.63 <sup>(2)</sup>	24,995	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		155	D	\$559.25 <sup>(3)</sup>	24,840	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		232	D	\$560.31 <sup>(4)</sup>	24,608	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		92	D	\$561.96 <sup>(5)</sup>	24,516	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		33	D	\$562.77	24,483	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		66	D	\$563.63 <sup>(6)</sup>	24,417	D	
Common Stock	04/17/2020	)	S <sup>(1)</sup>		44	D	\$565.77	24,373	D	
Common Stock	04/17/2020	)	M <sup>(1)</sup>		12,500	Α	\$272.7	36,873	D	
Common Stock	04/17/2020	)	F <sup>(1)</sup>		9,250	D	\$555.82	27,623	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		35	D	\$562.71	27,588	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		225	D	\$563.74 <sup>(7)</sup>	27,363	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		340	D	\$564.76(8)	27,023	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		902	D	\$565.52 <sup>(9)</sup>	26,121	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		944	D	\$566.44(10)	25,177	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		114	D	\$567.76	25,063	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		126	D	\$568.11(11)	24,937	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		66	D	\$569.22 <sup>(12)</sup>	24,871	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		114	D	\$571.65	24,757	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		64	D	\$572.42(13)	24,693	D	
Common Stock	04/20/2020	)	S <sup>(1)</sup>		320	D	\$573.4 <sup>(14)</sup>	24,373	D	
Common Stock								200	I	By 401(k) Plan

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$272.7	04/16/2020		<b>M</b> <sup>(1)</sup>			4,000	(15)	09/09/2023	Common Stock	4,000	\$0.0	31,500	D	
Non- Qualified Stock Option (right to buy)	\$272.7	04/17/2020		M <sup>(1)</sup>			12,500	(15)	09/09/2023	Common Stock	12,500	\$0.0	19,000	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

## **Explanation of Responses:**

- 1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- 2. Represents volume-weighted average price of sales of 89 shares of Company stock on April 17, 2020 at prices ranging from \$558.61 to \$558.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
- 3. Represents volume-weighted average price of sales of 155 shares of Company stock on April 17, 2020 at prices ranging from \$559.21 to \$559.39. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
- 4. Represents volume-weighted average price of sales of 232 shares of Company stock on April 17, 2020 at prices ranging from \$560.02 to \$560.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
- 5. Represents volume-weighted average price of sales of 92 shares of Company stock on April 17, 2020 at prices ranging from \$561.92 to \$561.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
- 6. Represents volume-weighted average price of sales of 66 shares of Company stock on April 17, 2020 at prices ranging from \$563.39 to \$563.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
- 7. Represents volume-weighted average price of sales of 225 shares of Company stock on April 20, 2020 at prices ranging from \$563.56 to \$563.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 8. Represents volume-weighted average price of sales of 340 shares of Company stock on April 20, 2020 at prices ranging from \$564.14 to \$564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 9. Represents volume-weighted average price of sales of 902 shares of Company stock on April 20, 2020 at prices ranging from \$565.05 to \$565.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 10. Represents volume-weighted average price of sales of 944 shares of Company stock on April 20, 2020 at prices ranging from \$566.01 to \$566.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 11. Represents volume-weighted average price of sales of 126 shares of Company stock on April 20, 2020 at prices ranging from \$568.10 to \$568.17. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 12. Represents volume-weighted average price of sales of 66 shares of Company stock on April 20, 2020 at prices ranging from \$569.10 to \$569.33. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 13. Represents volume-weighted average price of sales of 64 shares of Company stock on April 20, 2020 at prices ranging from \$572.19 to \$572.48. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 14. Represents volume-weighted average price of sales of 320 shares of Company stock on April 20, 2020 at prices ranging from \$573.01 to \$573.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
- 15. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

<u>/s/\*\*Robert E. Landry</u> 04/20/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.